IP Group
VC Fund
London, United Kingdom
IP Group is a VC fund in London focused on Biotechnology and Health Care. IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and create value out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
- Total investments:
- 236
- Last investment:
- Lead investor:
- 22%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries IP Group invests in
Stages IP Group invests in
Countries IP Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 23 contacts → | |||
Round size
- Seed
- $208k–$7.6M
- Series A
- $2.4M–$30M
- Series B
- $7.9M–$68M
Investment Focus
Industry
- Biotechnology 37 (16%)
- Health Care 33 (14%)
- Information Technology 19 (8%)
- Software 18 (8%)
- Therapeutics 18 (8%)
Stage
- Seed 51 (22%)
- Series A 42 (18%)
- Series B 29 (12%)
- Venture - Series Unknown 26 (11%)
- Funding Round 16 (7%)
Country
- United Kingdom 99 (42%)
- United States 16 (7%)
- Australia 8 (3%)
- Sweden 2 (1%)
- New Zealand 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ben Murphey
Investment Director
|
Investment Director | Total investments: 2 | Find email | |
Dani Bach
Partner, Life Sciences
|
Partner, Life Sciences | Total investments: 3 | Find email | |
Greg Smith
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Jamie Vollbracht
Partner, Cleantech
|
Partner, Cleantech | Total investments: 3 | Find email | |
Manjari Chandran-Ramesh
Investment Director
|
Investment Director | Total investments: 7 | Find email | |
| See all 23 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Matter Machine
|
Matter Machine is an AI-driven materials discovery company that creates technologies that use materials chemistry, machine learning, and automated experimentation to speed up the discovery and optimization of next-generation materials. | $5.3M / Seed / Oct 12, 2026 | |
| Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity. | $9.4M / Seed / Jul 21, 2026 | ||
| Solving human problems with nature’s surfaces. | $19.3M / Series A / Jun 29, 2026 | ||
| SLAMcore’s mission is to make commercial-grade spatial intelligence accessible to allTheir team of world-leading spatial intelligence experts have developed advanced SLAM (simultaneous localization and mapping) software that allow robots and drones to truly understand the space around them.Spun out from Imperial College London, SLAMcore hascreated real-time, commercial grade, location, mapping and perception (SLAM) software for use in autonomous robots, drones and consumer products. The SLAMcore software enables fast prototyping and development of commercial products using visual SLAM software for autonomous location, mapping and perception. The software runs in real-time on standard compute/sensors and can be customised for commercial products using cost-effective custom compute/sensors. The team includes industry leading SLAM experts, roboticists, engineers and developers. Pushing the boundaries of what's possible today and how visual SLAM will look like tomorrow. Through partnership with OEMs, SLAMcore provides the core technology that allows robots to become a meaningful part of everyday life. | $14M / May 27, 2026 | ||
| Mantle8 is a natural hydrogen exploration company. It has developed geological models and imaging technologies that detect the best natural hydrogen locations with “world-first accuracy“ | $36.4M / Series A / May 13, 2026 | ||
| Barocal is a Zero-carbon refrigeration pioneer. | $10M / Seed / May 04, 2026 | ||
| Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging. | $23M / Series A / Apr 29, 2026 | ||
| Alesi Surgical was founded in 2009 to develop and commercialise products that improve the safety, efficacy and outcomes of surgical procedures. The company is a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experiencedsurgeons, surgical trainers and trainees, which allows it to identify issues in procedures and design devices to address these issues. | $7M / Venture - Series Unknown / Apr 21, 2026 | ||
| First Light Fusion was spun out from the University of Oxford and focuses on researching energy generation by inertial confinement fusion. Its platform explores a number of alternative research directions that harness fundamental physics focusing on power generation and theoretical analysis, detailed numerical simulation, and experimentalvalidation that helps clients to discover a new source of energy. The company directly employs a team of engineers and physicists and collaborates closely with a number of academic organizations, including the University of Oxford, Warwick University, UCL, and Imperial College, London.The company was founded by Professor Yiannis Ventikos and Dr. Nicholas Hawker and is based in Yarnton, Oxfordshire. | $25M / Venture - Series Unknown / Apr 21, 2026 | ||
| Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $56M / Series C / Apr 16, 2026 | ||
| See all 236 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does IP Group invest in?
IP Group invests primarily in Biotechnology, Health Care and Information Technology startups, most often at Seed and Series A stage. Most of the 236 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does IP Group invest in?
IP Group typically joins rounds of $208k–$7.6M at Seed, $2.4M–$30M at Series A and $7.9M–$68M at Series B. These are whole funding-round sizes, not IP Group's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds IP Group took part in.
How do I contact IP Group?
Public channels for IP Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at IP Group?
The team at IP Group includes Ben Murphey (Investment Director), Dani Bach (Partner, Life Sciences) and Greg Smith (Chief Financial Officer), among 23 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
